K S Tewari1, J J Java2, R N Eskander3, B J Monk4, R A Burger5. 1. University of California, Irvine Medical Center, Orange, California ktewari@uci.edu. 2. NRG Oncology/Gynecologic Oncology Group Statistics and Data Management Center, Roswell Park Cancer Institute, Buffalo. 3. University of California, Irvine Medical Center, Orange, California. 4. Creighton University School of Medicine, St Joseph's Hospital and Medical Center, Phoenix. 5. Obstetrics and Gynecology, University of Pennsylvania, Pennsylvania, USA.
Abstract
BACKGROUND: To determine whether time from surgery to initiation of chemotherapy impacts survival in advanced ovarian carcinoma. PATIENTS AND METHODS: This is a post-trial ad hoc analysis of Gynecologic Oncology Group protocol 218, a phase III randomized, double-blind, placebo-controlled trial designed to study the antiangiogenesis agent, bevacizumab, in primary and maintenance therapy for patients with newly diagnosed advanced ovarian carcinoma. Maximum attempt at debulking was an eligibility criterion. Stage III patients, not stage IV, were required to have gross macroscopic or palpable residual disease following surgery. The survival impact of time from surgery to initiation of chemotherapy was studied using Cox regression models and stratified by treatment arm, residual disease and other clinical and pathologic factors. RESULTS:One thousand seven hundred eighteen assessable patients were randomized (stage III (n = 1237); stage IV (n = 477), including those with complete resection (stage IV only, n = 81), low-volume residual (≤1 cm, n = 701), and suboptimal (>1 cm, n = 932). On multivariate analysis, time to chemotherapy initiation was predictive of overall survival (P < 0.001), with the complete resection group (i.e. stage IV) encountering an increased risk of death when time to initiation of chemotherapy exceeded 25 days (95% confidence interval 16.6-49.9 days). CONCLUSION:Survival for women with advanced ovarian cancer may be adversely affected when initiation of chemotherapy occurs >25 days following surgery. Our analysis applies to stage IV only as women with stage III who underwent complete resection were not eligible for this trial. These results, however, are consistent with Gompertzian first-order kinetics where patients with microscopic residual are most vulnerable. CLINICAL TRIALS IDENTIFIER: NCT00262847.
RCT Entities:
BACKGROUND: To determine whether time from surgery to initiation of chemotherapy impacts survival in advanced ovarian carcinoma. PATIENTS AND METHODS: This is a post-trial ad hoc analysis of Gynecologic Oncology Group protocol 218, a phase III randomized, double-blind, placebo-controlled trial designed to study the antiangiogenesis agent, bevacizumab, in primary and maintenance therapy for patients with newly diagnosed advanced ovarian carcinoma. Maximum attempt at debulking was an eligibility criterion. Stage III patients, not stage IV, were required to have gross macroscopic or palpable residual disease following surgery. The survival impact of time from surgery to initiation of chemotherapy was studied using Cox regression models and stratified by treatment arm, residual disease and other clinical and pathologic factors. RESULTS: One thousand seven hundred eighteen assessable patients were randomized (stage III (n = 1237); stage IV (n = 477), including those with complete resection (stage IV only, n = 81), low-volume residual (≤1 cm, n = 701), and suboptimal (>1 cm, n = 932). On multivariate analysis, time to chemotherapy initiation was predictive of overall survival (P < 0.001), with the complete resection group (i.e. stage IV) encountering an increased risk of death when time to initiation of chemotherapy exceeded 25 days (95% confidence interval 16.6-49.9 days). CONCLUSION: Survival for women with advanced ovarian cancer may be adversely affected when initiation of chemotherapy occurs >25 days following surgery. Our analysis applies to stage IV only as women with stage III who underwent complete resection were not eligible for this trial. These results, however, are consistent with Gompertzian first-order kinetics where patients with microscopic residual are most vulnerable. CLINICAL TRIALS IDENTIFIER: NCT00262847.
Authors: Jason D Wright; Thomas J Herzog; Alfred I Neugut; William M Burke; Yu-Shiang Lu; Sharyn N Lewin; Dawn L Hershman Journal: Obstet Gynecol Date: 2012-10 Impact factor: 7.661
Authors: Claudia Allemani; Hannah K Weir; Helena Carreira; Rhea Harewood; Devon Spika; Xiao-Si Wang; Finian Bannon; Jane V Ahn; Christopher J Johnson; Audrey Bonaventure; Rafael Marcos-Gragera; Charles Stiller; Gulnar Azevedo e Silva; Wan-Qing Chen; Olufemi J Ogunbiyi; Bernard Rachet; Matthew J Soeberg; Hui You; Tomohiro Matsuda; Magdalena Bielska-Lasota; Hans Storm; Thomas C Tucker; Michel P Coleman Journal: Lancet Date: 2014-11-26 Impact factor: 79.321
Authors: Dawn L Hershman; Xiaoyan Wang; Russell McBride; Judith S Jacobson; Victor R Grann; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2006-04-01 Impact factor: 4.872
Authors: G Hofstetter; N Concin; I Braicu; R Chekerov; J Sehouli; I Cadron; T Van Gorp; F Trillsch; S Mahner; H Ulmer; C Grimm; D Cacsire Castillo-Tong; R Zeillinger; A G Zeimet; I Vergote Journal: Gynecol Oncol Date: 2013-07-20 Impact factor: 5.482
Authors: Dipak Panigrahy; Allison Gartung; Jun Yang; Haixia Yang; Molly M Gilligan; Megan L Sulciner; Swati S Bhasin; Diane R Bielenberg; Jaimie Chang; Birgitta A Schmidt; Julia Piwowarski; Anna Fishbein; Dulce Soler-Ferran; Matthew A Sparks; Steven J Staffa; Vidula Sukhatme; Bruce D Hammock; Mark W Kieran; Sui Huang; Manoj Bhasin; Charles N Serhan; Vikas P Sukhatme Journal: J Clin Invest Date: 2019-06-17 Impact factor: 14.808
Authors: John K Chan; James J Java; Katherine Fuh; Bradley J Monk; Daniel S Kapp; Thomas Herzog; Jeffrey Bell; Robert Young Journal: Gynecol Oncol Date: 2016-10-19 Impact factor: 5.482
Authors: Krishnansu S Tewari; Robert A Burger; Danielle Enserro; Barbara M Norquist; Elizabeth M Swisher; Mark F Brady; Michael A Bookman; Gini F Fleming; Helen Huang; Howard D Homesley; Jeffrey M Fowler; Benjamin E Greer; Matthew Boente; Sharon X Liang; Chenglin Ye; Carlos Bais; Leslie M Randall; John K Chan; J Stuart Ferriss; Robert L Coleman; Carol Aghajanian; Thomas J Herzog; Philip J DiSaia; Larry J Copeland; Robert S Mannel; Michael J Birrer; Bradley J Monk Journal: J Clin Oncol Date: 2019-06-19 Impact factor: 44.544
Authors: Xiang Li; Shaomin Wang; Wei Mu; Jennifer Barry; Anna Han; Richard L Carpenter; Bing-Hua Jiang; Stephen C Peiper; Mỹ G Mahoney; Andrew E Aplin; Hong Ren; Jun He Journal: J Exp Clin Cancer Res Date: 2022-01-27
Authors: Andrew Bryant; Shaun Hiu; Patience T Kunonga; Ketankumar Gajjar; Dawn Craig; Luke Vale; Brett A Winter-Roach; Ahmed Elattar; Raj Naik Journal: Cochrane Database Syst Rev Date: 2022-09-26
Authors: Renee A Cowan; Jill Tseng; Vijayashree Murthy; Radhika Srivastava; Kara C Long Roche; Oliver Zivanovic; Ginger J Gardner; Dennis S Chi; Bernard J Park; Yukio Sonoda Journal: Gynecol Oncol Date: 2017-09-06 Impact factor: 5.482
Authors: Arlene E Garcia-Soto; James J Java; Wilberto Nieves Neira; J Matthew Pearson; David E Cohn; Shashikant B Lele; Krishnansu S Tewari; Joan L Walker; Angeles Alvarez Secord; Deborah K Armstrong; Larry J Copeland Journal: Gynecol Oncol Date: 2016-10-07 Impact factor: 5.482
Authors: Benjamin B Albright; Dimitrios Nasioudis; Stuart Craig; Haley A Moss; Nawar A Latif; Emily M Ko; Ashley F Haggerty Journal: Am J Obstet Gynecol Date: 2020-08-07 Impact factor: 8.661